United Kingdom User Evaluation, MiniMed Paradigm® X54 System (X54User)
This study has been completed.
Sponsor:
Medtronic Diabetes
Information provided by:
Medtronic Diabetes
ClinicalTrials.gov Identifier:
NCT01267175
First received: December 23, 2010
Last updated: February 16, 2011
Last verified: February 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The user evaluation is to assess user acceptance and the quality of training materials for the MiniMed Paradigm® X54 System (X54 System) in preparation for commercial distribution of the new system.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus, Type 1 |
Device: X54 insulin pump with low suspend feature |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | United Kingdom User Evaluation, MiniMed Paradigm® X54 System |
Resource links provided by NLM:
Genetics Home Reference related topics:
type 1 diabetes
Drug Information available for:
Insulin human
U.S. FDA Resources
Further study details as provided by Medtronic Diabetes:
Primary Outcome Measures:
- Usability of the X54 Insulin Pump Meets Expectations [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]Questionnaire completed at the end of the study measuring usability of the X54 insulin pump. Results scored on a Likert scale of 1 - 7, 1 being the least likely to use and 7 being the most likely to use.
Secondary Outcome Measures:
- Usability of the Training Material Meets Expectations [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]Questionnaire completed at the end of the study, measuring usability of the device training manual. Results scored on a Likert scale of 1 - 7, 1 being the least user friendly and 7 being the most user friendly.
| Enrollment: | 31 |
| Study Start Date: | January 2009 |
| Study Completion Date: | February 2009 |
| Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: X54 pump
All subjects transferred from current pump to X54
|
Device: X54 insulin pump with low suspend feature
Change from current insulin pump to new X54 pump
Other Name: Veo
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Are current 512/712, 515/715 or 522/722 MiniMed Paradigm Insulin Pump users, with or without CGM experience, and have at least three months experience with any one of these devices;
- Have signed an Informed Consent and are willing to comply with the user evaluation procedures;
- Have an HbA1c value less than 9.0% recorded at the time of their last test (if no HbA1c value is available within three months of enrollment, an HbA1c should be performed prior to entry to verify inclusion criteria);
- Are willing to use the Bolus Wizard feature;
- Agree to complete a diary for the duration of the study;
- Agree to complete a questionnaire at the conclusion of the study;
- Have been diagnosed with Type 1 Diabetes Mellitus by appropriate fasting or non fasting lab blood glucose values, c-peptide, insulin antibodies, prior documented DKA or good clinical picture at least six months prior to study start;
- Are 18 - 65 years of age;
- Have access to the internet and agree to upload the device per protocol
Exclusion Criteria:
- Is pregnant or planning to become pregnant during the course of the user evaluation. Pregnancy screening will be completed during the routine office visit prior to evaluation for the study. If a woman becomes pregnant during participation, she will be withdrawn;
- Suffers from a chronic debilitating condition;
- Has serious or unstable medical or psychological conditions (e.g., eating disorders, clinical depression, anxiety disorder) which, in the opinion of the Investigator, would compromise the subject's safety or successful participation in the study;
- Has impaired vision or hearing problems that could compromise the handling of the device;
- Has a history of tape allergies or skin conditions that could interfere with continued use of the system;
- Has the potential for lack of compliance or any other issue, in the opinion of the Investigator, that may preclude the subject from satisfactory participation in the study;
- Has travel plans which would make it difficult for the subject to attend on-site study visits as scheduled;
- Is currently participating in an investigational study (drug or device).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01267175
Locations
| United Kingdom | |
| Addenbrookes Hospital | |
| Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ | |
| Royal Bournemouth Hospital | |
| Bournemouth, Dorset, United Kingdom, BH7 7DW | |
| Kings College Hospital | |
| Denmark Hill, London, United Kingdom, SE5 9RS | |
| Harrogate District Hospital | |
| Harrogate, N. Yorkshire, United Kingdom, HG2 7SX | |
| Newcastle General Hospital | |
| Newcastle Upon Tyne, Tyne and Wear, United Kingdom, NE4 6BE | |
| Guy's Hospital | |
| London, United Kingdom, SE1 9RT | |
Sponsors and Collaborators
Medtronic Diabetes
Investigators
| Study Director: | Scott W Lee, MD | Medtronic |
More Information
No publications provided by Medtronic Diabetes
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Scott Lee, MD, Medtronic |
| ClinicalTrials.gov Identifier: | NCT01267175 History of Changes |
| Other Study ID Numbers: | ETP08-2625 |
| Study First Received: | December 23, 2010 |
| Results First Received: | January 21, 2011 |
| Last Updated: | February 16, 2011 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases |
Immune System Diseases Insulin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 17, 2013